Mazdutide Research Guide

Full name: Mazdutide (Dual GLP-1/Glucagon Agonist)

A dual GLP-1/glucagon receptor agonist with promising weight loss results comparable to tirzepatide, including additional hepatic fat reduction.

How Mazdutide Works

Dual activation of GLP-1 receptors for appetite suppression combined with glucagon receptor activation for enhanced hepatic lipid oxidation and energy expenditure.

Dosing Protocol

• Typical dose: 3-9 mg
• Frequency: Once weekly
• Duration: Ongoing
• Route: Subcutaneous

Reported Benefits

• Significant weight loss (up to 18%)
• Liver fat reduction
• Improved insulin sensitivity
• Once-weekly convenience
• Potential MASH benefit

Potential Side Effects

• Nausea
• Diarrhea
• Decreased appetite
• Injection site reactions

Research Citations

1. Phase 3 mazdutide for obesity in Chinese adults (2024) - Mazdutide 9mg produced 17.3% weight loss at 48 weeks with improved metabolic parameters.
2. Mazdutide effects on hepatic steatosis (2023) - 60-70% reduction in hepatic fat content measured by MRI-PDFF at 24 weeks.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Mazdutide profile with 3D molecule viewer →